PathAI

We’re thrilled to share that 𝐏𝐚𝐭𝐡𝐀𝐈 has been recognized for the “𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐭𝐡𝐞 𝐘𝐞𝐚𝐫” by the 𝐁𝐢𝐨𝐓𝐞𝐜𝐡 𝐁𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐀𝐰𝐚𝐫𝐝𝐬! 🎉 Our 𝐀𝐈𝐒𝐢𝐠𝐡𝐭® 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦 earned this prestigious award for its transformative impact on pathology workflows, integrating cutting-edge AI to power digital #pathology adoption. A huge thank you to our team, partners, and the pathology community for making this achievement possible. Together, we’re redefining what’s possible for #digitalpathology! 💡 Learn more about AISight® and how it’s shaping the future of pathology: https://lnkd.in/eEJrGCMC #AIPathology #PathAI #BioTechBreakthrough #AISight #DigitalPathology

🚀 We’re thrilled to announce PathAI is a Deloitte Technology Fast 500™ Winner! This recognition highlights our rapid growth and innovation in transforming pathology with AI-powered tools. From enabling #digitalpathology workflows through AISight® to supporting #drugdevelopment with cutting-edge #biopharma solutions, we’re redefining the field. 🔗 Read the #PressRelease: https://lnkd.in/ehtz5hyC Thank you to our team, partners, and the community driving this exciting journey forward! 🚀 #TechFast500 #AI #Pathology #Innovation #Deloitte #TechnologyFast500 #Fast500 #CancerResearch #AIPathology 𝘈𝘐𝘚𝘪𝘨𝘩𝘵® 𝘪𝘴 𝘧𝘰𝘳 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘜𝘴𝘦 𝘖𝘯𝘭𝘺 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘚; 𝘈𝘐𝘚𝘪𝘨𝘩𝘵 𝘋𝘹 𝘪𝘴 𝘊𝘌-𝘐𝘝𝘋 𝘪𝘯 𝘌𝘶𝘳𝘰𝘱𝘦 𝘢𝘯𝘥 𝘜𝘒𝘊𝘈 𝘪𝘯 𝘜𝘒

🇫🇷 Bonjour! We are live at CARREFOUR #PATHOLOGIE 2024 at the iconic CNIT Forest in Paris La Défense! Stop by booth 21 to see #AIPathology in action and live demos of AISight®. Meet with Max Zinner, Suzana Vega Harring MD MBA, and Vincent Billaut to discover how AISight Dx IMS is revolutionizing pathology workflows and enhancing case management to drive efficiency and precision in pathology lab processes. Learn more about AISight®: https://lnkd.in/ef5NWxse 𝘈𝘐𝘚𝘪𝘨𝘩𝘵® 𝘪𝘴 𝘧𝘰𝘳 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘜𝘴𝘦 𝘖𝘯𝘭𝘺 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘚; 𝘈𝘐𝘚𝘪𝘨𝘩𝘵 𝘋𝘹 𝘪𝘴 𝘊𝘌-𝘐𝘝𝘋 𝘪𝘯 𝘌𝘶𝘳𝘰𝘱𝘦 𝘢𝘯𝘥 𝘜𝘒𝘊𝘈 𝘪𝘯 𝘜𝘒 🇫🇷 Bonjour à tous ! Nous sommes en direct de CARREFOUR PATHOLOGIE 2024, au CNIT Forest à Paris La Défense ! Passez au stand 21 pour découvrir l’#IAenPathologie en action avec des démonstrations en direct d’AISight®.Rencontrez Max Zinner, Suzana Vega Harring MD MBA, Vincent Billaut et découvrez comment notre système de gestion d’images « AISight Dx » révolutionne les flux de travail en pathologie et améliore la gestion des cas pour optimiser l’efficacité et la précision des processus en laboratoire de pathologie. En savoir plus sur AISight® : https://lnkd.in/epFBqjwy 𝘈𝘐𝘚𝘪𝘨𝘩𝘵 𝘋𝘹 𝘦𝘴𝘵 𝘤𝘦𝘳𝘵𝘪𝘧𝘪é 𝘊𝘌-𝘐𝘝𝘋 𝘦𝘯 𝘌𝘶𝘳𝘰𝘱𝘦 𝘦𝘵 𝘜𝘒𝘊𝘈 𝘢𝘶 𝘙𝘰𝘺𝘢𝘶𝘮𝘦-𝘜𝘯𝘪, 𝘈𝘐𝘚𝘪𝘨𝘩𝘵 𝘦𝘴𝘵 𝘳é𝘴𝘦𝘳𝘷é à 𝘭𝘢 𝘳𝘦𝘤𝘩𝘦𝘳𝘤𝘩𝘦 𝘢𝘶𝘹 É𝘵𝘢𝘵𝘴-𝘜𝘯𝘪𝘴. #Pathology #AI #AIPathology #biotech #Pathologie #CAREFOURPATHOLOGIE #CAREFOURPATHOLOGIE2024 #anatomicpathology #biotech #biotechnology

📣 Upcoming #Webinar: AI-Powered Pathology for #MASH & Liver Disease Research and Drug Development 📅 Friday, December 6th 🕚 11AM - 12PM ET 💻 Panelists: Eric Walk MD, FCAP, Christina Jayson, Ph.D., Lara P. Murray, PhD, Ylaine Gerardin, Adam Stanford-Moore Join us for an insightful session exploring the groundbreaking role of AI-powered pathology in advancing MASH and liver disease research through drug development! This free webinar offers a unique look at our Liver Explore™ tool, designed to provide high-resolution insights into tissue biology and #fibrosis microarchitecture. 𝐖𝐡𝐚𝐭 𝐲𝐨𝐮’𝐥𝐥 𝐥𝐞𝐚𝐫𝐧: - Histological insights that can be uniquely captured by AI-powered pathology - An inside look at building AI tools specifically for liver disease research - Live demonstration of Liver Explore™  - Case studies and guidance on leveraging AI-powered insights in MASH and liver disease - An overview of Liver Explore™’s versatility in MASH and non-MASH liver disease applications Register now to learn how our tools are transforming liver disease insights and drug development! #Pathology #AI #MASH #LiverDisease #DrugDevelopment #Liver #LiverResearch #healthtech #AIPathology #DigitalPathology 𝘓𝘪𝘷𝘦𝘳𝘌𝘹𝘱𝘭𝘰𝘳𝘦™ 𝘪𝘴 𝘧𝘰𝘳 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘕𝘰𝘵 𝘧𝘰𝘳 𝘶𝘴𝘦 𝘪𝘯 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤 𝘱𝘳𝘰𝘤𝘦𝘥𝘶𝘳𝘦𝘴.

We're excited to announce partnerships and integrations with several leading #AI digital pathology companies - Deep Bio Inc., DoMore Diagnostics, Paige, and Visiopharm - through our AISight® Image Management System! 🔗 Read the #PressRelease: https://lnkd.in/eTqX-tKw These partnerships will enable seamless access for pathologists to top-tier AI algorithms, boosting #pathology workflow efficiency, #biomarker quantification, risk stratification, and more. PathAI is committed to offering the most versatile, reliable, and interoperable IMS on the market. This is a major step forward in bringing cutting-edge technologies to the fingertips of #pathologists, to enhance #diagnostics and improve patient outcomes. Learn more or contact us at digitaldx@pathai.com. #DigitalPathology #Innovation #Partnerships #AISight #biotech #biotechnology #AIinHealthcare #healthtech -AISight® is for Research Use Only in the US; AISight Dx is CE-IVD in Europe and UKCA in UK

Today is the last day of AASLD's The Liver Meeting! Thank you to those who have visited PathAI’s booth and met with our amazing team about using #AIPathology for #MASH and #LiverDisease research and #drugdevelopment.  Feel free to stop by our booth in the next few hours to see live demos of Liver Explore™ AIM-MASH+ and AIM-MASH AI-Assist from our scientific team and round out another incredible year.  Here’s to American Association for the Study of Liver Diseases (AASLD)’s #TLM24! 🎉 𝘓𝘪𝘷𝘦𝘳 𝘌𝘹𝘱𝘭𝘰𝘳𝘦™, 𝘈𝘐𝘔-𝘔𝘈𝘚𝘏+, 𝘢𝘯𝘥 𝘈𝘐𝘔-𝘔𝘈𝘚𝘏 𝘈𝘐-𝘈𝘴𝘴𝘪𝘴𝘵 𝘢𝘳𝘦 𝘧𝘰𝘳 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘕𝘰𝘵 𝘧𝘰𝘳 𝘶𝘴𝘦 𝘪𝘯 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤 𝘱𝘳𝘰𝘤𝘦𝘥𝘶𝘳𝘦𝘴. 

We are thankful to the Hoag Health System for inviting our Global Head of Commercial, Digital Diagnostics, Parth Chodavadia, MD to showcase PathAI’s AISightⓇ #ImageManagementSystem at the recent Hoag Board of Directors retreat! We are energized by our partnership with Hoag as well as the potential for #digitalpathology and #AI in health systems. #IMS #AISight #ArtificialIntelligence #AIPathology #pathology 𝘈𝘐𝘚𝘪𝘨𝘩𝘵 𝘪𝘴 𝘧𝘰𝘳 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘕𝘰𝘵 𝘧𝘰𝘳 𝘶𝘴𝘦 𝘪𝘯 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤 𝘱𝘳𝘰𝘤𝘦𝘥𝘶𝘳𝘦𝘴. Pictured 📸: David R. Braxton M.D. (Chief of Molecular Pathology, Hoag Hospital), Anisha Gururaj (Senior Manager, Sales and Partnerships - Digital Diagnostics, PathAI), and Parth Chodavadia, MD (Global Head of Commercial - Digital Diagnostics, PathAI)

We’re excited to share that PathAI scientists have recently published “𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐯𝐚𝐥𝐢𝐝𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐚𝐧 𝐀𝐈-𝐛𝐚𝐬𝐞𝐝 𝐩𝐚𝐭𝐡𝐨𝐥𝐨𝐠𝐲 𝐭𝐨𝐨𝐥 𝐟𝐨𝐫 𝐬𝐜𝐨𝐫𝐢𝐧𝐠 𝐨𝐟 𝐦𝐞𝐭𝐚𝐛𝐨𝐥𝐢𝐜 𝐝𝐲𝐬𝐟𝐮𝐧𝐜𝐭𝐢𝐨𝐧-𝐚𝐬𝐬𝐨𝐜𝐢𝐚𝐭𝐞𝐝 𝐬𝐭𝐞𝐚𝐭𝐨𝐡𝐞𝐩𝐚𝐭𝐢𝐭𝐢𝐬” in Nature Magazine which details our latest advances in AI-powered pathology for MASH. This comprehensive, multisite study validates AIM-MASH AI outputs and AI-assisted pathologist workflow, designed to enhance histology scoring in MASH trials. Read the paper: https://lnkd.in/gez_4SgK 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: - AIM-MASH demonstrated high repeatability and reproducibility compared to traditional manual scoring. - AIM-MASH-assisted assessments by expert pathologists provided greater accuracy in evaluating inflammation, ballooning, and MASH resolution. - This AI-driven tool addresses reader variability, delivering a potentially more reliable assessment for evaluating MASH therapeutics. - With limited treatment options for MASH, AIM-MASH promises to be a game-changer for clinical trials, providing a standardized, AI-assisted scoring approach that enhances reliability and consistency. #Pathology #MASH #AI #LiverDisease #ClinicalResearch #DigitalPathology #HealthcareInnovation 𝘈𝘐𝘔-𝘔𝘈𝘚𝘏 𝘪𝘴 𝘧𝘰𝘳 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘕𝘰𝘵 𝘧𝘰𝘳 𝘶𝘴𝘦 𝘪𝘯 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤 𝘱𝘳𝘰𝘤𝘦𝘥𝘶𝘳𝘦𝘴.

PathAI is excited to participate in CARREFOUR PATHOLOGIE 2024, taking place from 20 to 22 November at the iconic CNIT Forest in Paris La Défense. Organized by the Société Française de Pathologie, this premier event is a hub for innovation and progress in pathology. Don’t miss the chance to meet with our team and discover how AISight Dx IMS is revolutionizing pathology workflows and enhancing case management to drive efficiency and precision in pathology lab processes. Visit us at booth #21 to explore how AISight supports pathologists in making accurate and efficient assessments. 📅 Book your demo here: https://lnkd.in/gA5-ZAYw #CARREFOURPATHOLOGIE2024 #PathAI #DigitalPathology #AIPoweredHealthcare #AnatomicPathology

We’re attending American Association for the Study of Liver Diseases (AASLD)'s 75th Annual Liver Meeting #TLM24 this year in San Diego, California! Stop by booth 1645 to meet our team, discuss the utilization of #AIPathology for #MASH and #LiverDisease research and #drugdevelopment, and get live demos of Liver Explore™ AIM-MASH+ and AIM-MASH AI-Assist from our scientific team. Can’t make it? Visit our virtual booth: https://lnkd.in/eTVsBzUN Our scientific program includes both partner presentations & posters and we will be presenting novel data for approaches to #fibrosis assessment. We look forward to connecting with you!  Saturday, November 16th 1:00 - 2:00 PM - Poster #2078 : 𝐀𝐝𝐣𝐮𝐬𝐭𝐢𝐧𝐠 𝐟𝐨𝐫 𝐒𝐭𝐞𝐚𝐭𝐨𝐬𝐢𝐬 𝐂𝐨𝐧𝐭𝐞𝐧𝐭 𝐢𝐧 𝐁𝐚𝐬𝐞𝐥𝐢𝐧𝐞 𝐚𝐧𝐝 𝐅𝐨𝐥𝐥𝐨𝐰-𝐮𝐩 𝐌𝐀𝐒𝐇 𝐁𝐢𝐨𝐩𝐬𝐢𝐞𝐬 𝐂𝐚𝐧 𝐎𝐯𝐞𝐫𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞 𝐂𝐡𝐚𝐧𝐠𝐞𝐬 𝐢𝐧 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬, Lara P. Murray, PhD Saturday, November 16th 1:00 - 2:00 PM - Poster #2011 : 𝐌𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐃𝐏/𝐀𝐈 𝐪𝐮𝐚𝐧𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡𝐞𝐬 𝐚𝐫𝐞 𝐜𝐨𝐦𝐩𝐥𝐢𝐦𝐞𝐧𝐭𝐚𝐫𝐲 𝐢𝐧 𝐢𝐝𝐞𝐧𝐭𝐢𝐟𝐲𝐢𝐧𝐠 𝐡𝐢𝐬𝐭𝐨𝐥𝐨𝐠𝐲 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐬: 𝐜𝐫𝐨𝐬𝐬 𝐬𝐞𝐜𝐭𝐢𝐨𝐧𝐚𝐥 𝐬𝐭𝐮𝐝𝐲 𝐢𝐧 𝐚 𝐉𝐚𝐩𝐚𝐧𝐞𝐬𝐞 𝐜𝐨𝐡𝐨𝐫𝐭, In partnership with Takeda Development Center Americas, Inc. Monday, November 18th 11:15 - 11:30 AM - Oral Presentation #163: 𝐀𝐈-𝐃𝐞𝐫𝐢𝐯𝐞𝐝 𝐆𝐫𝐚𝐧𝐮𝐥𝐚𝐫 𝐇𝐢𝐬𝐭𝐨𝐥𝐨𝐠𝐢𝐜𝐚𝐥 𝐌𝐚𝐫𝐤𝐞𝐫𝐬 𝐨𝐟 𝐈𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐢𝐨𝐧 & 𝐅𝐢𝐛𝐫𝐨𝐬𝐢𝐬 𝐀𝐬𝐬𝐨𝐜𝐢𝐚𝐭𝐞 𝐰𝐢𝐭𝐡 𝐏𝐫𝐨𝐠𝐫𝐞𝐬𝐬𝐢𝐨𝐧 𝐢𝐧 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐀𝐥𝐜𝐨𝐡𝐨𝐥-𝐑𝐞𝐥𝐚𝐭𝐞𝐝 𝐒𝐭𝐞𝐚𝐭𝐨𝐡𝐞𝐩𝐚𝐭𝐢𝐭𝐢𝐬, In partnership with Mayo Clinic 𝘓𝘪𝘷𝘦𝘳 𝘌𝘹𝘱𝘭𝘰𝘳𝘦™, 𝘈𝘐𝘔-𝘔𝘈𝘚𝘏+, 𝘢𝘯𝘥 𝘈𝘐𝘔-𝘔𝘈𝘚𝘏 𝘈𝘐-𝘈𝘴𝘴𝘪𝘴𝘵 𝘢𝘳𝘦 𝘧𝘰𝘳 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘶𝘴𝘦 𝘰𝘯𝘭𝘺. 𝘕𝘰𝘵 𝘧𝘰𝘳 𝘶𝘴𝘦 𝘪𝘯 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤 𝘱𝘳𝘰𝘤𝘦𝘥𝘶𝘳𝘦𝘴.